Thymidine Kinase 2 Deficiency - KYGEVVI, A Breakthrough

General
, ,
1

What is Thymidine Kinase 2 Deficiency (TK2d)?
TK2 deficiency, a rare genetic autosomal recessive inherited disorder, where the energy production from mitochondria is impaired, primarily affecting muscle function.

Causes:

  • Genetic mutation - Mutation in the TK2 gene
  • Inheritance pattern - Autosomal recessive inheritance’
  • Enzyme dysfunction - Deficiency of TK2 enzyme

Symptoms:

  • Muscle weakness (especially, limbs and respiratory muscles)
  • Difficulty in swallowing or speaking
  • Fatigue
  • Respiratory failure in advanced cases
  • Developmental delays

KYGEVVI - A Treatment Breakthrough

A combination of doxecitine and doxribtimine, approved by the FDA on 3 November 2025. KYGEVVI is the first-ever treatment approved by the FDA for the treatment of TK2d.

Clinical impact:

  • Up to 94% reduction in death risk for early-onset patients
  • 75% regained motor milestones
  • 16% reduced or discontinued ventilatory support

Adverse effects - Generally well tolerated, but diarrhea was the most common adverse event.

Do you know any other rare genetic conditions with no well-established treatment strategies?

MBH/AB

2 Likes
2

Yes, there are some rare genetic conditions that still don’t have a clear treatment. Progeria, Niemann-Pick Type C, and FOP. For many of these, doctors mainly focus on supportive care because no definite cure or standard treatment exists yet.

3

Exactly, more funding is required for developing treatments or medicine for such conditions that are rare. But, due to lack of profits to the pharmaceutical firms, focus on these areas of research is usually limited.

1 Like